Moderna study shows its COVID-19 vaccine holds up against several variants after six months_老虎社区_美港股上老虎

Moderna study shows its COVID-19 vaccine holds up against several variants after six months

Market Wacth2021-08-13

Moderna Inc. shares ticked higher in the extended session Thursday afetr the biotech drug company said a study showed its COVID-19 vaccine held up against several variants of the virus that causes the...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

MrInvestor
·2021-08-13
Price will go up
回复
3
举报
收起
- jimmylaw:
  comment bck
  2021-08-13
  回复
  举报
Soojj
·2021-08-13
Ok
回复
5
举报
收起
- Soojj:
  Ok
  2021-08-13
  回复
  举报
Bull_Lion
·2021-08-13
Sweet! Lucky I picked Moderna as my vaccine 😀
回复
1
举报
woonws
·2021-08-13
Good for those vaccinated with Moderna, and good for Moderna investors!
回复
3
举报
收起
- IvanOon:
  Agree
  2021-08-13
  回复
  举报
fortuna
·2021-08-13
Like
回复
1
举报

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1109187442?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-08-13 14:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1109187442","market":"us","top_or_hot":-1,"title":"Moderna study shows its COVID-19 vaccine holds up against several variants after six months","media":"Market Wacth","content":"<div>\n<p>Moderna Inc. shares ticked higher in the extended session Thursday afetr the biotech drug company said a study showed its COVID-19 vaccine held up against several variants of the virus that causes the...</p>\n\n<a href=\"https://www.marketwatch.com/story/moderna-study-shows-its-covid-19-vaccine-holds-up-against-several-variants-after-six-months-11628803856?mod=home-page\">网页链接</a>\n\n</div>\n","source":"lsy1604288433698","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna study shows its COVID-19 vaccine holds up against several variants after six months</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna study shows its COVID-19 vaccine holds up against several variants after six months\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-13 14:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/moderna-study-shows-its-covid-19-vaccine-holds-up-against-several-variants-after-six-months-11628803856?mod=home-page><strong>Market Wacth</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc. shares ticked higher in the extended session Thursday afetr the biotech drug company said a study showed its COVID-19 vaccine held up against several variants of the virus that causes the...</p>\n\n<a href=\"https://www.marketwatch.com/story/moderna-study-shows-its-covid-19-vaccine-holds-up-against-several-variants-after-six-months-11628803856?mod=home-page\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"https://www.marketwatch.com/story/moderna-study-shows-its-covid-19-vaccine-holds-up-against-several-variants-after-six-months-11628803856?mod=home-page","article_id":"1109187442","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1109187442","pubTimestamp":1628834960,"columns":[],"sourceInfo":{"source_id":"lsy1604288433698","name":"Market Wacth"},"weMediaInfo":null,"summary":"Moderna Inc. shares ticked higher in the extended session Thursday afetr the biotech drug company sa","collect":0,"end_time":0,"defaultTopTitle":"marketwatch.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"莫德纳的一项研究显示，其新冠肺炎疫苗在六个月后能抵抗几种变体","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":0.9},"content_text":"Moderna Inc. shares ticked higher in the extended session Thursday afetr the biotech drug company said a study showed its COVID-19 vaccine held up against several variants of the virus that causes the disease.\nThe study was tested against SARS-CoV-2 variants that included alpha, beta, gamma, delta epsilon, and iota, ModernaMRNA,+1.58%said. While the patients given two doses of Moderna COVID-19 vaccine had some “waning in antibody levels,” the majority had enough antibodies to neutralize the virus at the six-month mark, the company said.\n“These data support the durable efficacy of 93% seen with the Moderna COVID-19 vaccine through six months,” said Stéphane Bancel, chief executive of Moderna, in a statement.\n“We expect that these data and the growing body of real-world evidence will help inform health regulators’ approaches to how and when to administer additional boosting doses,” Bancel said.\nShares rose 0.7% after-hours, following a 1.6% rise in the regular session to close at $391.42. The stock is up 463% over the past 12 months, compared with a 32% gain on the S&P 500 indexSPX,+0.30%.","kind":"news","is_publish_news":false,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[{"id":894538719,"gmtCreate":1628837234731,"gmtModify":1631893810434,"author":{"id":"3586672191897597","authorId":"3586672191897597","name":"MrInvestor","avatar":"https://static.tigerbbs.com/40974a38cd623c0089adf8fd12d91591","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"idStr":"3586672191897597","authorIdStr":"3586672191897597"},"htmlText":"Price will go up","listText":"Price will go up","text":"Price will go up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/894538719","repostId":1109187442,"repostType":4,"repost":{"id":"1109187442","kind":"news","pubTimestamp":1628834960,"share":"https://www.laohu8.com/m/news/1109187442?lang=zh_CN&edition=full","pubTime":"2021-08-13 14:09","market":"us","language":"en","title":"Moderna study shows its COVID-19 vaccine holds up against several variants after six months<blockquote>Moderna研究显示其COVID-19疫苗在六个月后仍能抵抗多种变种</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1109187442","media":"Market Wacth","summary":"Moderna Inc. shares ticked higher in the extended session Thursday afetr the biotech drug company sa","content":"<p>Moderna Inc. shares ticked higher in the extended session Thursday afetr the biotech drug company said a study showed its COVID-19 vaccine held up against several variants of the virus that causes the disease.</p><p><blockquote>Moderna Inc.股价在周四的延长交易中走高，此前这家生物技术制药公司表示，一项研究显示其COVID-19疫苗可以抵抗导致该疾病的几种病毒变种。</blockquote></p><p> The study was tested against SARS-CoV-2 variants that included alpha, beta, gamma, delta epsilon, and iota, ModernaMRNA,+1.58%said. While the patients given two doses of Moderna COVID-19 vaccine had some “waning in antibody levels,” the majority had enough antibodies to neutralize the virus at the six-month mark, the company said.</p><p><blockquote>ModernaMRNA+1.58%表示，这项研究针对包括alpha、beta、gamma、delta epsilon和iota在内的新型冠状病毒病毒变异体进行了测试。该公司表示，虽然接种两剂Moderna COVID-19疫苗的患者“抗体水平有所下降”，但大多数人在六个月时有足够的抗体来中和病毒。</blockquote></p><p> “These data support the durable efficacy of 93% seen with the Moderna COVID-19 vaccine through six months,” said Stéphane Bancel, chief executive of Moderna, in a statement.</p><p><blockquote>Moderna首席执行官Stéphane Bancel在一份声明中表示：“这些数据支持Moderna COVID-19疫苗在六个月内的持久功效为93%。”</blockquote></p><p> “We expect that these data and the growing body of real-world evidence will help inform health regulators’ approaches to how and when to administer additional boosting doses,” Bancel said.</p><p><blockquote>班塞尔说：“我们预计这些数据和越来越多的现实世界证据将有助于为卫生监管机构确定如何以及何时施用额外的加强剂量提供信息。”</blockquote></p><p> Shares rose 0.7% after-hours, following a 1.6% rise in the regular session to close at $391.42. The stock is up 463% over the past 12 months, compared with a 32% gain on the S&amp;P 500 indexSPX,+0.30%.</p><p><blockquote>盘后股价上涨0.7%，常规交易时段上涨1.6%，收于391.42美元。该股在过去12个月内上涨了463%，而标普500指数SPX上涨了32%，+0.30%。</blockquote></p><p></p>","source":"lsy1604288433698","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna study shows its COVID-19 vaccine holds up against several variants after six months<blockquote>Moderna研究显示其COVID-19疫苗在六个月后仍能抵抗多种变种</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna study shows its COVID-19 vaccine holds up against several variants after six months<blockquote>Moderna研究显示其COVID-19疫苗在六个月后仍能抵抗多种变种</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Market Wacth</strong><span class=\"h-time small\">2021-08-13 14:09</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Moderna Inc. shares ticked higher in the extended session Thursday afetr the biotech drug company said a study showed its COVID-19 vaccine held up against several variants of the virus that causes the disease.</p><p><blockquote>Moderna Inc.股价在周四的延长交易中走高，此前这家生物技术制药公司表示，一项研究显示其COVID-19疫苗可以抵抗导致该疾病的几种病毒变种。</blockquote></p><p> The study was tested against SARS-CoV-2 variants that included alpha, beta, gamma, delta epsilon, and iota, ModernaMRNA,+1.58%said. While the patients given two doses of Moderna COVID-19 vaccine had some “waning in antibody levels,” the majority had enough antibodies to neutralize the virus at the six-month mark, the company said.</p><p><blockquote>ModernaMRNA+1.58%表示，这项研究针对包括alpha、beta、gamma、delta epsilon和iota在内的新型冠状病毒病毒变异体进行了测试。该公司表示，虽然接种两剂Moderna COVID-19疫苗的患者“抗体水平有所下降”，但大多数人在六个月时有足够的抗体来中和病毒。</blockquote></p><p> “These data support the durable efficacy of 93% seen with the Moderna COVID-19 vaccine through six months,” said Stéphane Bancel, chief executive of Moderna, in a statement.</p><p><blockquote>Moderna首席执行官Stéphane Bancel在一份声明中表示：“这些数据支持Moderna COVID-19疫苗在六个月内的持久功效为93%。”</blockquote></p><p> “We expect that these data and the growing body of real-world evidence will help inform health regulators’ approaches to how and when to administer additional boosting doses,” Bancel said.</p><p><blockquote>班塞尔说：“我们预计这些数据和越来越多的现实世界证据将有助于为卫生监管机构确定如何以及何时施用额外的加强剂量提供信息。”</blockquote></p><p> Shares rose 0.7% after-hours, following a 1.6% rise in the regular session to close at $391.42. The stock is up 463% over the past 12 months, compared with a 32% gain on the S&amp;P 500 indexSPX,+0.30%.</p><p><blockquote>盘后股价上涨0.7%，常规交易时段上涨1.6%，收于391.42美元。该股在过去12个月内上涨了463%，而标普500指数SPX上涨了32%，+0.30%。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.marketwatch.com/story/moderna-study-shows-its-covid-19-vaccine-holds-up-against-several-variants-after-six-months-11628803856?mod=home-page\">Market Wacth</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.marketwatch.com/story/moderna-study-shows-its-covid-19-vaccine-holds-up-against-several-variants-after-six-months-11628803856?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1109187442","content_text":"Moderna Inc. shares ticked higher in the extended session Thursday afetr the biotech drug company said a study showed its COVID-19 vaccine held up against several variants of the virus that causes the disease.\nThe study was tested against SARS-CoV-2 variants that included alpha, beta, gamma, delta epsilon, and iota, ModernaMRNA,+1.58%said. While the patients given two doses of Moderna COVID-19 vaccine had some “waning in antibody levels,” the majority had enough antibodies to neutralize the virus at the six-month mark, the company said.\n“These data support the durable efficacy of 93% seen with the Moderna COVID-19 vaccine through six months,” said Stéphane Bancel, chief executive of Moderna, in a statement.\n“We expect that these data and the growing body of real-world evidence will help inform health regulators’ approaches to how and when to administer additional boosting doses,” Bancel said.\nShares rose 0.7% after-hours, following a 1.6% rise in the regular session to close at $391.42. The stock is up 463% over the past 12 months, compared with a 32% gain on the S&P 500 indexSPX,+0.30%.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5515311,"gmtCreate":1628837852202,"gmtModify":1631893810589,"authorId":3570772304712620,"author":{"id":3570772304712620,"idStr":"3570772304712620","authorId":3570772304712620,"name":"jimmylaw","avatar":"https://static.tigerbbs.com/f6c847ae11f03f4682632e6fa4016040","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":894538719,"type":1,"supId":0,"prevId":0,"content":"comment <u>bck</u>","text":"comment <u>bck</u>","html":"comment <u>bck</u>"}],"langContent":"EN"},{"id":894533477,"gmtCreate":1628837023099,"gmtModify":1631890349834,"author":{"id":"3582029553166690","authorId":"3582029553166690","name":"Soojj","avatar":"https://static.tigerbbs.com/2c7b0e3654b1b442172ea81a7188cb95","vip":1,"crmLevel":2,"crmLevelSwitch":0,"wearingBadges":[],"idStr":"3582029553166690","authorIdStr":"3582029553166690"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/894533477","repostId":1109187442,"repostType":4,"repost":{"id":"1109187442","kind":"news","pubTimestamp":1628834960,"share":"https://www.laohu8.com/m/news/1109187442?lang=zh_CN&edition=full","pubTime":"2021-08-13 14:09","market":"us","language":"en","title":"Moderna study shows its COVID-19 vaccine holds up against several variants after six months<blockquote>Moderna研究显示其COVID-19疫苗在六个月后仍能抵抗多种变种</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1109187442","media":"Market Wacth","summary":"Moderna Inc. shares ticked higher in the extended session Thursday afetr the biotech drug company sa","content":"<p>Moderna Inc. shares ticked higher in the extended session Thursday afetr the biotech drug company said a study showed its COVID-19 vaccine held up against several variants of the virus that causes the disease.</p><p><blockquote>Moderna Inc.股价在周四的延长交易中走高，此前这家生物技术制药公司表示，一项研究显示其COVID-19疫苗可以抵抗导致该疾病的几种病毒变种。</blockquote></p><p> The study was tested against SARS-CoV-2 variants that included alpha, beta, gamma, delta epsilon, and iota, ModernaMRNA,+1.58%said. While the patients given two doses of Moderna COVID-19 vaccine had some “waning in antibody levels,” the majority had enough antibodies to neutralize the virus at the six-month mark, the company said.</p><p><blockquote>ModernaMRNA+1.58%表示，这项研究针对包括alpha、beta、gamma、delta epsilon和iota在内的新型冠状病毒病毒变异体进行了测试。该公司表示，虽然接种两剂Moderna COVID-19疫苗的患者“抗体水平有所下降”，但大多数人在六个月时有足够的抗体来中和病毒。</blockquote></p><p> “These data support the durable efficacy of 93% seen with the Moderna COVID-19 vaccine through six months,” said Stéphane Bancel, chief executive of Moderna, in a statement.</p><p><blockquote>Moderna首席执行官Stéphane Bancel在一份声明中表示：“这些数据支持Moderna COVID-19疫苗在六个月内的持久功效为93%。”</blockquote></p><p> “We expect that these data and the growing body of real-world evidence will help inform health regulators’ approaches to how and when to administer additional boosting doses,” Bancel said.</p><p><blockquote>班塞尔说：“我们预计这些数据和越来越多的现实世界证据将有助于为卫生监管机构确定如何以及何时施用额外的加强剂量提供信息。”</blockquote></p><p> Shares rose 0.7% after-hours, following a 1.6% rise in the regular session to close at $391.42. The stock is up 463% over the past 12 months, compared with a 32% gain on the S&amp;P 500 indexSPX,+0.30%.</p><p><blockquote>盘后股价上涨0.7%，常规交易时段上涨1.6%，收于391.42美元。该股在过去12个月内上涨了463%，而标普500指数SPX上涨了32%，+0.30%。</blockquote></p><p></p>","source":"lsy1604288433698","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna study shows its COVID-19 vaccine holds up against several variants after six months<blockquote>Moderna研究显示其COVID-19疫苗在六个月后仍能抵抗多种变种</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna study shows its COVID-19 vaccine holds up against several variants after six months<blockquote>Moderna研究显示其COVID-19疫苗在六个月后仍能抵抗多种变种</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Market Wacth</strong><span class=\"h-time small\">2021-08-13 14:09</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Moderna Inc. shares ticked higher in the extended session Thursday afetr the biotech drug company said a study showed its COVID-19 vaccine held up against several variants of the virus that causes the disease.</p><p><blockquote>Moderna Inc.股价在周四的延长交易中走高，此前这家生物技术制药公司表示，一项研究显示其COVID-19疫苗可以抵抗导致该疾病的几种病毒变种。</blockquote></p><p> The study was tested against SARS-CoV-2 variants that included alpha, beta, gamma, delta epsilon, and iota, ModernaMRNA,+1.58%said. While the patients given two doses of Moderna COVID-19 vaccine had some “waning in antibody levels,” the majority had enough antibodies to neutralize the virus at the six-month mark, the company said.</p><p><blockquote>ModernaMRNA+1.58%表示，这项研究针对包括alpha、beta、gamma、delta epsilon和iota在内的新型冠状病毒病毒变异体进行了测试。该公司表示，虽然接种两剂Moderna COVID-19疫苗的患者“抗体水平有所下降”，但大多数人在六个月时有足够的抗体来中和病毒。</blockquote></p><p> “These data support the durable efficacy of 93% seen with the Moderna COVID-19 vaccine through six months,” said Stéphane Bancel, chief executive of Moderna, in a statement.</p><p><blockquote>Moderna首席执行官Stéphane Bancel在一份声明中表示：“这些数据支持Moderna COVID-19疫苗在六个月内的持久功效为93%。”</blockquote></p><p> “We expect that these data and the growing body of real-world evidence will help inform health regulators’ approaches to how and when to administer additional boosting doses,” Bancel said.</p><p><blockquote>班塞尔说：“我们预计这些数据和越来越多的现实世界证据将有助于为卫生监管机构确定如何以及何时施用额外的加强剂量提供信息。”</blockquote></p><p> Shares rose 0.7% after-hours, following a 1.6% rise in the regular session to close at $391.42. The stock is up 463% over the past 12 months, compared with a 32% gain on the S&amp;P 500 indexSPX,+0.30%.</p><p><blockquote>盘后股价上涨0.7%，常规交易时段上涨1.6%，收于391.42美元。该股在过去12个月内上涨了463%，而标普500指数SPX上涨了32%，+0.30%。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.marketwatch.com/story/moderna-study-shows-its-covid-19-vaccine-holds-up-against-several-variants-after-six-months-11628803856?mod=home-page\">Market Wacth</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.marketwatch.com/story/moderna-study-shows-its-covid-19-vaccine-holds-up-against-several-variants-after-six-months-11628803856?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1109187442","content_text":"Moderna Inc. shares ticked higher in the extended session Thursday afetr the biotech drug company said a study showed its COVID-19 vaccine held up against several variants of the virus that causes the disease.\nThe study was tested against SARS-CoV-2 variants that included alpha, beta, gamma, delta epsilon, and iota, ModernaMRNA,+1.58%said. While the patients given two doses of Moderna COVID-19 vaccine had some “waning in antibody levels,” the majority had enough antibodies to neutralize the virus at the six-month mark, the company said.\n“These data support the durable efficacy of 93% seen with the Moderna COVID-19 vaccine through six months,” said Stéphane Bancel, chief executive of Moderna, in a statement.\n“We expect that these data and the growing body of real-world evidence will help inform health regulators’ approaches to how and when to administer additional boosting doses,” Bancel said.\nShares rose 0.7% after-hours, following a 1.6% rise in the regular session to close at $391.42. The stock is up 463% over the past 12 months, compared with a 32% gain on the S&P 500 indexSPX,+0.30%.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5515246,"gmtCreate":1628837038924,"gmtModify":1635152589909,"authorId":3582029553166690,"author":{"id":3582029553166690,"idStr":"3582029553166690","authorId":3582029553166690,"name":"Soojj","avatar":"https://static.tigerbbs.com/2c7b0e3654b1b442172ea81a7188cb95","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":894533477,"type":1,"supId":0,"prevId":0,"content":"<u>Ok</u>","text":"<u>Ok</u>","html":"<u>Ok</u>"}],"langContent":"EN"},{"id":894530346,"gmtCreate":1628836756085,"gmtModify":1633689089310,"author":{"id":"3573540190522229","authorId":"3573540190522229","name":"Bull_Lion","avatar":"https://static.tigerbbs.com/97c7d011186160cd333508e7d9191f74","vip":1,"crmLevel":12,"crmLevelSwitch":0,"wearingBadges":[],"idStr":"3573540190522229","authorIdStr":"3573540190522229"},"htmlText":"Sweet! Lucky I picked Moderna as my vaccine 😀","listText":"Sweet! Lucky I picked Moderna as my vaccine 😀","text":"Sweet! Lucky I picked Moderna as my vaccine 😀","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/894530346","repostId":1109187442,"repostType":4,"repost":{"id":"1109187442","kind":"news","pubTimestamp":1628834960,"share":"https://www.laohu8.com/m/news/1109187442?lang=zh_CN&edition=full","pubTime":"2021-08-13 14:09","market":"us","language":"en","title":"Moderna study shows its COVID-19 vaccine holds up against several variants after six months<blockquote>Moderna研究显示其COVID-19疫苗在六个月后仍能抵抗多种变种</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1109187442","media":"Market Wacth","summary":"Moderna Inc. shares ticked higher in the extended session Thursday afetr the biotech drug company sa","content":"<p>Moderna Inc. shares ticked higher in the extended session Thursday afetr the biotech drug company said a study showed its COVID-19 vaccine held up against several variants of the virus that causes the disease.</p><p><blockquote>Moderna Inc.股价在周四的延长交易中走高，此前这家生物技术制药公司表示，一项研究显示其COVID-19疫苗可以抵抗导致该疾病的几种病毒变种。</blockquote></p><p> The study was tested against SARS-CoV-2 variants that included alpha, beta, gamma, delta epsilon, and iota, ModernaMRNA,+1.58%said. While the patients given two doses of Moderna COVID-19 vaccine had some “waning in antibody levels,” the majority had enough antibodies to neutralize the virus at the six-month mark, the company said.</p><p><blockquote>ModernaMRNA+1.58%表示，这项研究针对包括alpha、beta、gamma、delta epsilon和iota在内的新型冠状病毒病毒变异体进行了测试。该公司表示，虽然接种两剂Moderna COVID-19疫苗的患者“抗体水平有所下降”，但大多数人在六个月时有足够的抗体来中和病毒。</blockquote></p><p> “These data support the durable efficacy of 93% seen with the Moderna COVID-19 vaccine through six months,” said Stéphane Bancel, chief executive of Moderna, in a statement.</p><p><blockquote>Moderna首席执行官Stéphane Bancel在一份声明中表示：“这些数据支持Moderna COVID-19疫苗在六个月内的持久功效为93%。”</blockquote></p><p> “We expect that these data and the growing body of real-world evidence will help inform health regulators’ approaches to how and when to administer additional boosting doses,” Bancel said.</p><p><blockquote>班塞尔说：“我们预计这些数据和越来越多的现实世界证据将有助于为卫生监管机构确定如何以及何时施用额外的加强剂量提供信息。”</blockquote></p><p> Shares rose 0.7% after-hours, following a 1.6% rise in the regular session to close at $391.42. The stock is up 463% over the past 12 months, compared with a 32% gain on the S&amp;P 500 indexSPX,+0.30%.</p><p><blockquote>盘后股价上涨0.7%，常规交易时段上涨1.6%，收于391.42美元。该股在过去12个月内上涨了463%，而标普500指数SPX上涨了32%，+0.30%。</blockquote></p><p></p>","source":"lsy1604288433698","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna study shows its COVID-19 vaccine holds up against several variants after six months<blockquote>Moderna研究显示其COVID-19疫苗在六个月后仍能抵抗多种变种</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna study shows its COVID-19 vaccine holds up against several variants after six months<blockquote>Moderna研究显示其COVID-19疫苗在六个月后仍能抵抗多种变种</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Market Wacth</strong><span class=\"h-time small\">2021-08-13 14:09</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Moderna Inc. shares ticked higher in the extended session Thursday afetr the biotech drug company said a study showed its COVID-19 vaccine held up against several variants of the virus that causes the disease.</p><p><blockquote>Moderna Inc.股价在周四的延长交易中走高，此前这家生物技术制药公司表示，一项研究显示其COVID-19疫苗可以抵抗导致该疾病的几种病毒变种。</blockquote></p><p> The study was tested against SARS-CoV-2 variants that included alpha, beta, gamma, delta epsilon, and iota, ModernaMRNA,+1.58%said. While the patients given two doses of Moderna COVID-19 vaccine had some “waning in antibody levels,” the majority had enough antibodies to neutralize the virus at the six-month mark, the company said.</p><p><blockquote>ModernaMRNA+1.58%表示，这项研究针对包括alpha、beta、gamma、delta epsilon和iota在内的新型冠状病毒病毒变异体进行了测试。该公司表示，虽然接种两剂Moderna COVID-19疫苗的患者“抗体水平有所下降”，但大多数人在六个月时有足够的抗体来中和病毒。</blockquote></p><p> “These data support the durable efficacy of 93% seen with the Moderna COVID-19 vaccine through six months,” said Stéphane Bancel, chief executive of Moderna, in a statement.</p><p><blockquote>Moderna首席执行官Stéphane Bancel在一份声明中表示：“这些数据支持Moderna COVID-19疫苗在六个月内的持久功效为93%。”</blockquote></p><p> “We expect that these data and the growing body of real-world evidence will help inform health regulators’ approaches to how and when to administer additional boosting doses,” Bancel said.</p><p><blockquote>班塞尔说：“我们预计这些数据和越来越多的现实世界证据将有助于为卫生监管机构确定如何以及何时施用额外的加强剂量提供信息。”</blockquote></p><p> Shares rose 0.7% after-hours, following a 1.6% rise in the regular session to close at $391.42. The stock is up 463% over the past 12 months, compared with a 32% gain on the S&amp;P 500 indexSPX,+0.30%.</p><p><blockquote>盘后股价上涨0.7%，常规交易时段上涨1.6%，收于391.42美元。该股在过去12个月内上涨了463%，而标普500指数SPX上涨了32%，+0.30%。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.marketwatch.com/story/moderna-study-shows-its-covid-19-vaccine-holds-up-against-several-variants-after-six-months-11628803856?mod=home-page\">Market Wacth</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.marketwatch.com/story/moderna-study-shows-its-covid-19-vaccine-holds-up-against-several-variants-after-six-months-11628803856?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1109187442","content_text":"Moderna Inc. shares ticked higher in the extended session Thursday afetr the biotech drug company said a study showed its COVID-19 vaccine held up against several variants of the virus that causes the disease.\nThe study was tested against SARS-CoV-2 variants that included alpha, beta, gamma, delta epsilon, and iota, ModernaMRNA,+1.58%said. While the patients given two doses of Moderna COVID-19 vaccine had some “waning in antibody levels,” the majority had enough antibodies to neutralize the virus at the six-month mark, the company said.\n“These data support the durable efficacy of 93% seen with the Moderna COVID-19 vaccine through six months,” said Stéphane Bancel, chief executive of Moderna, in a statement.\n“We expect that these data and the growing body of real-world evidence will help inform health regulators’ approaches to how and when to administer additional boosting doses,” Bancel said.\nShares rose 0.7% after-hours, following a 1.6% rise in the regular session to close at $391.42. The stock is up 463% over the past 12 months, compared with a 32% gain on the S&P 500 indexSPX,+0.30%.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":894592858,"gmtCreate":1628836119474,"gmtModify":1633689091229,"author":{"id":"3581999478634265","authorId":"3581999478634265","name":"woonws","avatar":"https://static.tigerbbs.com/f26ed1a10ee84ab97229aad191ef3133","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"idStr":"3581999478634265","authorIdStr":"3581999478634265"},"htmlText":"Good for those vaccinated with Moderna, and good for Moderna investors!","listText":"Good for those vaccinated with Moderna, and good for Moderna investors!","text":"Good for those vaccinated with Moderna, and good for Moderna investors!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/894592858","repostId":1109187442,"repostType":4,"repost":{"id":"1109187442","kind":"news","pubTimestamp":1628834960,"share":"https://www.laohu8.com/m/news/1109187442?lang=zh_CN&edition=full","pubTime":"2021-08-13 14:09","market":"us","language":"en","title":"Moderna study shows its COVID-19 vaccine holds up against several variants after six months<blockquote>Moderna研究显示其COVID-19疫苗在六个月后仍能抵抗多种变种</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1109187442","media":"Market Wacth","summary":"Moderna Inc. shares ticked higher in the extended session Thursday afetr the biotech drug company sa","content":"<p>Moderna Inc. shares ticked higher in the extended session Thursday afetr the biotech drug company said a study showed its COVID-19 vaccine held up against several variants of the virus that causes the disease.</p><p><blockquote>Moderna Inc.股价在周四的延长交易中走高，此前这家生物技术制药公司表示，一项研究显示其COVID-19疫苗可以抵抗导致该疾病的几种病毒变种。</blockquote></p><p> The study was tested against SARS-CoV-2 variants that included alpha, beta, gamma, delta epsilon, and iota, ModernaMRNA,+1.58%said. While the patients given two doses of Moderna COVID-19 vaccine had some “waning in antibody levels,” the majority had enough antibodies to neutralize the virus at the six-month mark, the company said.</p><p><blockquote>ModernaMRNA+1.58%表示，这项研究针对包括alpha、beta、gamma、delta epsilon和iota在内的新型冠状病毒病毒变异体进行了测试。该公司表示，虽然接种两剂Moderna COVID-19疫苗的患者“抗体水平有所下降”，但大多数人在六个月时有足够的抗体来中和病毒。</blockquote></p><p> “These data support the durable efficacy of 93% seen with the Moderna COVID-19 vaccine through six months,” said Stéphane Bancel, chief executive of Moderna, in a statement.</p><p><blockquote>Moderna首席执行官Stéphane Bancel在一份声明中表示：“这些数据支持Moderna COVID-19疫苗在六个月内的持久功效为93%。”</blockquote></p><p> “We expect that these data and the growing body of real-world evidence will help inform health regulators’ approaches to how and when to administer additional boosting doses,” Bancel said.</p><p><blockquote>班塞尔说：“我们预计这些数据和越来越多的现实世界证据将有助于为卫生监管机构确定如何以及何时施用额外的加强剂量提供信息。”</blockquote></p><p> Shares rose 0.7% after-hours, following a 1.6% rise in the regular session to close at $391.42. The stock is up 463% over the past 12 months, compared with a 32% gain on the S&amp;P 500 indexSPX,+0.30%.</p><p><blockquote>盘后股价上涨0.7%，常规交易时段上涨1.6%，收于391.42美元。该股在过去12个月内上涨了463%，而标普500指数SPX上涨了32%，+0.30%。</blockquote></p><p></p>","source":"lsy1604288433698","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna study shows its COVID-19 vaccine holds up against several variants after six months<blockquote>Moderna研究显示其COVID-19疫苗在六个月后仍能抵抗多种变种</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna study shows its COVID-19 vaccine holds up against several variants after six months<blockquote>Moderna研究显示其COVID-19疫苗在六个月后仍能抵抗多种变种</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Market Wacth</strong><span class=\"h-time small\">2021-08-13 14:09</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Moderna Inc. shares ticked higher in the extended session Thursday afetr the biotech drug company said a study showed its COVID-19 vaccine held up against several variants of the virus that causes the disease.</p><p><blockquote>Moderna Inc.股价在周四的延长交易中走高，此前这家生物技术制药公司表示，一项研究显示其COVID-19疫苗可以抵抗导致该疾病的几种病毒变种。</blockquote></p><p> The study was tested against SARS-CoV-2 variants that included alpha, beta, gamma, delta epsilon, and iota, ModernaMRNA,+1.58%said. While the patients given two doses of Moderna COVID-19 vaccine had some “waning in antibody levels,” the majority had enough antibodies to neutralize the virus at the six-month mark, the company said.</p><p><blockquote>ModernaMRNA+1.58%表示，这项研究针对包括alpha、beta、gamma、delta epsilon和iota在内的新型冠状病毒病毒变异体进行了测试。该公司表示，虽然接种两剂Moderna COVID-19疫苗的患者“抗体水平有所下降”，但大多数人在六个月时有足够的抗体来中和病毒。</blockquote></p><p> “These data support the durable efficacy of 93% seen with the Moderna COVID-19 vaccine through six months,” said Stéphane Bancel, chief executive of Moderna, in a statement.</p><p><blockquote>Moderna首席执行官Stéphane Bancel在一份声明中表示：“这些数据支持Moderna COVID-19疫苗在六个月内的持久功效为93%。”</blockquote></p><p> “We expect that these data and the growing body of real-world evidence will help inform health regulators’ approaches to how and when to administer additional boosting doses,” Bancel said.</p><p><blockquote>班塞尔说：“我们预计这些数据和越来越多的现实世界证据将有助于为卫生监管机构确定如何以及何时施用额外的加强剂量提供信息。”</blockquote></p><p> Shares rose 0.7% after-hours, following a 1.6% rise in the regular session to close at $391.42. The stock is up 463% over the past 12 months, compared with a 32% gain on the S&amp;P 500 indexSPX,+0.30%.</p><p><blockquote>盘后股价上涨0.7%，常规交易时段上涨1.6%，收于391.42美元。该股在过去12个月内上涨了463%，而标普500指数SPX上涨了32%，+0.30%。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.marketwatch.com/story/moderna-study-shows-its-covid-19-vaccine-holds-up-against-several-variants-after-six-months-11628803856?mod=home-page\">Market Wacth</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.marketwatch.com/story/moderna-study-shows-its-covid-19-vaccine-holds-up-against-several-variants-after-six-months-11628803856?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1109187442","content_text":"Moderna Inc. shares ticked higher in the extended session Thursday afetr the biotech drug company said a study showed its COVID-19 vaccine held up against several variants of the virus that causes the disease.\nThe study was tested against SARS-CoV-2 variants that included alpha, beta, gamma, delta epsilon, and iota, ModernaMRNA,+1.58%said. While the patients given two doses of Moderna COVID-19 vaccine had some “waning in antibody levels,” the majority had enough antibodies to neutralize the virus at the six-month mark, the company said.\n“These data support the durable efficacy of 93% seen with the Moderna COVID-19 vaccine through six months,” said Stéphane Bancel, chief executive of Moderna, in a statement.\n“We expect that these data and the growing body of real-world evidence will help inform health regulators’ approaches to how and when to administer additional boosting doses,” Bancel said.\nShares rose 0.7% after-hours, following a 1.6% rise in the regular session to close at $391.42. The stock is up 463% over the past 12 months, compared with a 32% gain on the S&P 500 indexSPX,+0.30%.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5515316,"gmtCreate":1628837908113,"gmtModify":1635152585491,"authorId":3569354683318638,"author":{"id":3569354683318638,"idStr":"3569354683318638","authorId":3569354683318638,"name":"IvanOon","avatar":"https://static.tigerbbs.com/7e332af04c99b1ae0ca2131246646a93","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":894592858,"type":1,"supId":0,"prevId":0,"content":"Agree","text":"Agree","html":"Agree"}],"langContent":"EN"},{"id":894590000,"gmtCreate":1628835402800,"gmtModify":1633689094944,"author":{"id":"3572304910905752","authorId":"3572304910905752","name":"fortuna","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":12,"crmLevelSwitch":0,"wearingBadges":[],"idStr":"3572304910905752","authorIdStr":"3572304910905752"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/894590000","repostId":1109187442,"repostType":4,"repost":{"id":"1109187442","kind":"news","pubTimestamp":1628834960,"share":"https://www.laohu8.com/m/news/1109187442?lang=zh_CN&edition=full","pubTime":"2021-08-13 14:09","market":"us","language":"en","title":"Moderna study shows its COVID-19 vaccine holds up against several variants after six months<blockquote>Moderna研究显示其COVID-19疫苗在六个月后仍能抵抗多种变种</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1109187442","media":"Market Wacth","summary":"Moderna Inc. shares ticked higher in the extended session Thursday afetr the biotech drug company sa","content":"<p>Moderna Inc. shares ticked higher in the extended session Thursday afetr the biotech drug company said a study showed its COVID-19 vaccine held up against several variants of the virus that causes the disease.</p><p><blockquote>Moderna Inc.股价在周四的延长交易中走高，此前这家生物技术制药公司表示，一项研究显示其COVID-19疫苗可以抵抗导致该疾病的几种病毒变种。</blockquote></p><p> The study was tested against SARS-CoV-2 variants that included alpha, beta, gamma, delta epsilon, and iota, ModernaMRNA,+1.58%said. While the patients given two doses of Moderna COVID-19 vaccine had some “waning in antibody levels,” the majority had enough antibodies to neutralize the virus at the six-month mark, the company said.</p><p><blockquote>ModernaMRNA+1.58%表示，这项研究针对包括alpha、beta、gamma、delta epsilon和iota在内的新型冠状病毒病毒变异体进行了测试。该公司表示，虽然接种两剂Moderna COVID-19疫苗的患者“抗体水平有所下降”，但大多数人在六个月时有足够的抗体来中和病毒。</blockquote></p><p> “These data support the durable efficacy of 93% seen with the Moderna COVID-19 vaccine through six months,” said Stéphane Bancel, chief executive of Moderna, in a statement.</p><p><blockquote>Moderna首席执行官Stéphane Bancel在一份声明中表示：“这些数据支持Moderna COVID-19疫苗在六个月内的持久功效为93%。”</blockquote></p><p> “We expect that these data and the growing body of real-world evidence will help inform health regulators’ approaches to how and when to administer additional boosting doses,” Bancel said.</p><p><blockquote>班塞尔说：“我们预计这些数据和越来越多的现实世界证据将有助于为卫生监管机构确定如何以及何时施用额外的加强剂量提供信息。”</blockquote></p><p> Shares rose 0.7% after-hours, following a 1.6% rise in the regular session to close at $391.42. The stock is up 463% over the past 12 months, compared with a 32% gain on the S&amp;P 500 indexSPX,+0.30%.</p><p><blockquote>盘后股价上涨0.7%，常规交易时段上涨1.6%，收于391.42美元。该股在过去12个月内上涨了463%，而标普500指数SPX上涨了32%，+0.30%。</blockquote></p><p></p>","source":"lsy1604288433698","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna study shows its COVID-19 vaccine holds up against several variants after six months<blockquote>Moderna研究显示其COVID-19疫苗在六个月后仍能抵抗多种变种</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna study shows its COVID-19 vaccine holds up against several variants after six months<blockquote>Moderna研究显示其COVID-19疫苗在六个月后仍能抵抗多种变种</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Market Wacth</strong><span class=\"h-time small\">2021-08-13 14:09</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Moderna Inc. shares ticked higher in the extended session Thursday afetr the biotech drug company said a study showed its COVID-19 vaccine held up against several variants of the virus that causes the disease.</p><p><blockquote>Moderna Inc.股价在周四的延长交易中走高，此前这家生物技术制药公司表示，一项研究显示其COVID-19疫苗可以抵抗导致该疾病的几种病毒变种。</blockquote></p><p> The study was tested against SARS-CoV-2 variants that included alpha, beta, gamma, delta epsilon, and iota, ModernaMRNA,+1.58%said. While the patients given two doses of Moderna COVID-19 vaccine had some “waning in antibody levels,” the majority had enough antibodies to neutralize the virus at the six-month mark, the company said.</p><p><blockquote>ModernaMRNA+1.58%表示，这项研究针对包括alpha、beta、gamma、delta epsilon和iota在内的新型冠状病毒病毒变异体进行了测试。该公司表示，虽然接种两剂Moderna COVID-19疫苗的患者“抗体水平有所下降”，但大多数人在六个月时有足够的抗体来中和病毒。</blockquote></p><p> “These data support the durable efficacy of 93% seen with the Moderna COVID-19 vaccine through six months,” said Stéphane Bancel, chief executive of Moderna, in a statement.</p><p><blockquote>Moderna首席执行官Stéphane Bancel在一份声明中表示：“这些数据支持Moderna COVID-19疫苗在六个月内的持久功效为93%。”</blockquote></p><p> “We expect that these data and the growing body of real-world evidence will help inform health regulators’ approaches to how and when to administer additional boosting doses,” Bancel said.</p><p><blockquote>班塞尔说：“我们预计这些数据和越来越多的现实世界证据将有助于为卫生监管机构确定如何以及何时施用额外的加强剂量提供信息。”</blockquote></p><p> Shares rose 0.7% after-hours, following a 1.6% rise in the regular session to close at $391.42. The stock is up 463% over the past 12 months, compared with a 32% gain on the S&amp;P 500 indexSPX,+0.30%.</p><p><blockquote>盘后股价上涨0.7%，常规交易时段上涨1.6%，收于391.42美元。该股在过去12个月内上涨了463%，而标普500指数SPX上涨了32%，+0.30%。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.marketwatch.com/story/moderna-study-shows-its-covid-19-vaccine-holds-up-against-several-variants-after-six-months-11628803856?mod=home-page\">Market Wacth</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.marketwatch.com/story/moderna-study-shows-its-covid-19-vaccine-holds-up-against-several-variants-after-six-months-11628803856?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1109187442","content_text":"Moderna Inc. shares ticked higher in the extended session Thursday afetr the biotech drug company said a study showed its COVID-19 vaccine held up against several variants of the virus that causes the disease.\nThe study was tested against SARS-CoV-2 variants that included alpha, beta, gamma, delta epsilon, and iota, ModernaMRNA,+1.58%said. While the patients given two doses of Moderna COVID-19 vaccine had some “waning in antibody levels,” the majority had enough antibodies to neutralize the virus at the six-month mark, the company said.\n“These data support the durable efficacy of 93% seen with the Moderna COVID-19 vaccine through six months,” said Stéphane Bancel, chief executive of Moderna, in a statement.\n“We expect that these data and the growing body of real-world evidence will help inform health regulators’ approaches to how and when to administer additional boosting doses,” Bancel said.\nShares rose 0.7% after-hours, following a 1.6% rise in the regular session to close at $391.42. The stock is up 463% over the past 12 months, compared with a 32% gain on the S&P 500 indexSPX,+0.30%.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":false,"newsSizeData":{"likeSize":24,"commentSize":5,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}